GlassScriptPhysician profile
George Anthony Rojas
NPI 1427039403
$8,567.84
in general payments reported to CMS, 2019-2025
34 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $516 · 2021: $1,140 · 2022: $1,748 · 2023: $1,233 · 2024: $1,662 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,402 · Education: $98.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,401.66 |
| Education | $98.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,356.72 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $1,008.28 | 2019-2025 | Farxiga |
| Horizon Therapeutics Plc | $523.42 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $486.39 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $473.73 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $465.07 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $459.36 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $452.00 | 2022-2025 | |
| Glaxosmithkline, LLC. | $351.30 | 2021-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.03 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $338.00 | 2021-2024 | Lupkynis |
| Vifor Pharma, INC. | $316.60 | 2019-2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $296.30 | 2023-2025 | |
| Akebia Therapeutics INC | $249.80 | 2019-2024 | Vafseo |
| Ani Pharmaceuticals, INC. | $196.85 | 2022-2024 | Purified Cortrophin Gel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $167.42 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $161.84 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $104.86 | 2022-2023 | |
| Ardelyx, INC. | $104.18 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $102.77 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $90.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.45 | 2021 | |
| Cormedix INC. | $69.09 | 2024 | Defencath |
| Arbor Pharmaceuticals, INC. | $68.36 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $55.68 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $48.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $35.59 | 2020-2021 | |
| Veloxis Pharmaceuticals, INC. | $33.90 | 2025 | Envarsus |
| Potrero Medical, INC. | $29.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.29 | 2019 | |
| Genzyme Corporation | $21.73 | 2019 | |
| Apellis Pharmaceuticals, INC. | $20.53 | 2025 | Empaveli |
| Nevro Corp. | $14.32 | 2024 | Senza |
| Lilly USA, LLC | $13.58 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.